Henriette Farkas

TL;DR: This supplement contains work presented at the third workshop and expanded content toward a definitive picture of angioedema in the absence of allergy, and includes cumulative genetic investigations; multinational laboratory diagnosis recommendations; current pathogenesis hypotheses; and suggested prophylaxis and acute attack treatment.

TL;DR: Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches.

TL;DR: Four types of acquired and three types of hereditary angioedema were identified as separate forms from the analysis of the literature and were presented in detail at the meeting.

TL;DR: In patients with hereditary angioedema having acute attacks, a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificantbenefit of ic atibant in the other trial are found with regard to the primary end point.

TL;DR: The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of H AE with deficient C1‐inhibitor (type 1) and HAE with dysfunctional C1-inhibitors (type 2).